New findings on tumor reduction and survival outcomes in advanced renal cell carcinoma
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
Targeted Oncology6d
Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC
Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...
ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinoma
Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...